Abstract: Synthetic methods provide for the simple, efficient preparation of amino polyols and derivatives. The methods include a three-component reaction of a carbohydrates with organoboron compounds and primary or secondary amine derivatives. The resulting amino polyols can be transformed into amino sugars. In one implementation, the amine moiety is protected, and an alkenyl, aryl or heteroaryl moiety is cleaved to form the amino sugar. Amino polyols and amino sugars prepared according to the methods are also described.

Abstract: A catalyst for the epoxidation of an olefin comprising a carrier and, deposited on the carrier, silver, a rhenium promoter, a first co-promoter, and a second co-promoter; wherein the quantity of the rhenium promoter deposited on the carrier is greater than 1 mmole/kg, relative to the weight of the catalyst; the first co-promoter is selected from sulfur, phosphorus, boron, and mixtures thereof; the second co-promoter is selected from tungsten, molybdenum, chromium, and mixtures thereof; and the total quantity of the first co-promoter and the second co-promoter deposited on the carrier is at most 3.8 mmole/kg, relative to the weight of the catalyst; a process for preparing the catalyst; a process for preparing an olefin oxide by reacting a feed comprising an olefin and oxygen in the presence of the catalyst; and a process for preparing a 1,2-diol, a 1,2-diol ether, a 1,2-carbonate, or an alkanolamine.

Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.

Abstract: The invention provides ionic liquids and processes for their preparation. The liquids may either comprise a cation of the formula (I); N+HR1R2R3 (I) wherein R1 is a group —R4—O—R5; R2 and R3 are each independently either hydrogen or hydrocarbyl, R2 and R3 may be joined together with the N to form a heterocyclic group; R4 is a divalent hydrocarbyl radical; and R5 is hydrocarbyl; or a cation of the formula (II), N+HR6R7R8 (II) wherein R6 is an alkanolyl group; R7 is a hydrocarbyl group; and R8 is either hydrogen or hydrocarbyl, or R7 and R8 may be joined together with the N to form a heterocyclic group.

Abstract: The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Abstract: A method of processing a substrate, including a step of processing an organic film pattern formed on a substrate, the step including, in sequence, a removal step of removing one of an alterated layer and a deposited layer formed on the organic film pattern, and a fusion/deformation step of fusing the organic film pattern for deformation, wherein at least a part of the removal step is carried out by applying chemical to the organic film pattern.

Abstract: In one embodiment, the present invention relates to amine-functionalized polyisobutylenes. Methods for preparing the amine-functionalized polyisobutylenes are also described. Furthermore, the invention relates to microemulsion coating compositions comprising the amine-functionalized polyisobutylenes which can be applied to various surfaces, especially metallic vehicle surfaces, wherein the compositions form a protective barrier on the surface and improve the drying rate, protection and shine of the surface. The coating compositions have a long service life and withstand numerous washing cycles. Moreover, the coating compositions when applied to surfaces, hydrophobize the same and allow for easy removal of water by increasing the contact angle of water droplets and thus reducing the “footprint” thereof.

Abstract: The invention relates to the use of an absorption liquid for purifying gases from gaseous acidic contaminants, the absorption liquid comprising A) 0.1 to 100% by weight of one or more amines of the formula I where R1 is H, C1-C6-alkyl, an aromatic radical having 6 to 18 carbon atoms or a radical of the formula 2 R2 is H, C1-C6-alkyl, an aromatic radical having 6 to 18 carbon atoms or a radical of the formula 3 R3 is C1-C6-alkyl or an aromatic radical having 6 to 18 carbon atoms R4 is H or CH3 R5 is H or CH3 x is a number from 0 to 3 y is a number from 0 to 3 z is an integer between 1 and 30, and also, if appropriate, B) 0 to 99.9% by weight of water, and/or C) 0 to 99.9% by weight of any desired solvent.

Abstract: A process for the preparation of compound of formula (I); wherein R1 is hydrogen, linear, branched or cyclic lower alkyl, cyclohexyl, allyl, propargyl or benzyl; R2 is hydrogen, methyl, ethyl or propyl; or R1 and R2 together with the nitogen to which they are attached form a cyclic moiety of three to eight-membered ring, with or without a hetero atom like nitrogen or oxygen; R3 is hydrogen or lower alkyl; R4 and R5 are the same or different and each is a lower alkyl; comprising reacting compound of formula (II); wherein R3, R4 and R5 are as defined above, with compound of formula (III); wherein R1 and R2 are as defined above, in the presence of a base, and further resolving the compound of formula (I) to obtain (S)-isomer of compound of formula (I), substantially free of R-isomer

Abstract: A process for treating a carrier, or a precursor thereof, to at least partly remove impurities comprising contacting the carrier, or the precursor thereof, with a treatment solution comprising a salt; a process for preparing a catalyst; the catalyst; a process for preparing an olefin oxide by reacting an olefin with oxygen in the presence of the catalyst; and a process for preparing a 1,2-diol, a 1,2-diol ether or an alkanolamine.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by -X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and

Abstract: The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Abstract: The present invention provides a process of starting from N-alkoxycarbonyl-ethylamine compounds having a leaving group at the ?-position to prepare oxazolidinone derivatives of ?-hydroxyethylamine compounds having an inverted steric configuration at the ?-position carbon, which comprises introducing a step of treating in contact with water with heating under acidic to neutral conditions into the process. Also, the present invention provides a process of starting from N-alkoxycarbonyl-ethylamine compounds having a leaving group at the ?-position to prepare ?-hydroxyethylamine compounds having an inverted steric configuration at the ?-position carbon, which comprises subjecting the oxazolidinone derivatives prepared as described above to a step of treating in contact with water under basic conditions.

Abstract: A method of selectively preparing a chiral 2S-amino alcohol useful in preparation of an amide sulfonated or acylated with alkyl, substituted aryl or substituted heteroaryl is described. The method involves reacting a di-tert-butyl diazene-1,2-dicarboxylate with a (4S)-4-benzyl-3-[(S)-trifluoromethyl-alkyl substituted alkanoyl]-1,3-oxazolidin-2-one to afford a di-tert-butyl 1-(1S,2S)-([(4S)-4-benzyl-2-oxo-1,3-oxazolidine-3-yl]-carbonyl}-trifluoromethyl-alkyl substituted alkyl)hydrazine-1,2-dicarboxylate. This dicarboxylate is then reduced to yield di-tert-butyl 1-(1S,2S)-[trifluoromethyl-alkyl substituted alkyl]hydrazine-1-(hydroxymethyl)-1,2-dicarboxylate. The resulting product is deblocked with an acid to yield the acid addition salt of (2S,3S)-trifluoro-hydrazino-methyl alkan-1-ol. The acid addition salt of (2S,3S)-trifluor-2-hydrazino-methyl alkan-1-ol is hydrogenated in the presence of a suitable metal catalyst to yield the amino alcohol (2S,3S)-2-amino-trifluoro-methyl alkan-1-ol HCl.

Abstract: The invention relates to a process for preparing optically active 2-amino-, 2-chloro-, 2-hydroxy- or 2-alkoxy-1-alcohols by catalytically hydrogenating appropriate optically active 2-amino-, 2-chloro-, 2-hydroxy- and 2-alkoxycarboxylic acids or their acid derivatives in the presence of catalysts comprising palladium and rhenium or platinum and rhenium.

Abstract: Disclosed are multibinding compounds which are ?2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

Abstract: A coating composition comprising a binder of a. polyisocyanate crosslinking agent; b. an isocyanate-reactive component having at least one compound having the following formula (I) including isomers and mixtures of isomers thereof: ?wherein ?R, R1, R2, X, Y, Z, m, n, p, q, r and s are described in the specification and a two component composition formulated with the above constituents and substrates, such as, automotive and truck bodies and parts coated with the novel composition and novel amine and/or hydroxy amine compounds are also part of the invention.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)1, or {(CH2)i—Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1—L?—X2—Z or —Z; R1–R6, independently of one another, are selected from the group consisting of H, —CH2)p—D—Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and

Abstract: This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1—L?—X2—Z or —Z; R1–R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D—Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and

Abstract: This application relates to the use of certain amines of formula (I) for combatting and preventing systemic and local complement activation, and in particular to the use of meglumine and derivatives and optionally salts thereof in combatting and preventing said activation. The amines are also of use in combatting activation of the kinin/kallikrein system or blood coagulation system.

Abstract: Compositions containing surfactant compounds according to formula (I) ROCH2CH(OH)CR1R2ZCR1R2CH(OH)CH2OR,??(I) wherein Z is S, SO, or SO2, can have a range of equilibrium and/or dynamic surface tensions and a range of foaming performance attributes, depending upon the particular values of Z, R, R1, and R2. The compounds of formula (I) may be prepared by a process that includes reaction of a sulfide source such as a metal sulfide or bisulfide with an alkyl glycidyl ether.

Abstract: The invention relates to processes for converting amino acids and amides to desirable conversion products including pyrrolidines, pyrrolidinones, and other N-substituted products. L-glutamic acid and L-pyroglutamic acid provide general reaction pathways to numerous and valuable selective conversion products with varied potential industrial uses.

Abstract: Intermediates used in the preparation of compounds of formula I, or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.

Abstract: A readily available and inexpensive natural ?-amino acid is converted into a compound represented by formula (1), which is then reacted with an organometallic reagent represented by formula (2) to give an optically active 5-hydroxyoxazolidine represented by formula (3), which is then treated with an acid to provide an optically active aminoketone represented by formula (4). The product is then converted into an optically active aminoalcohol represented by formula (5) or (6) by, for example reduction.

Abstract: Organic amine salts of compounds of the formula: and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

Abstract: Derivatives of bis-(1,3-dihydroxy-prop-2-yl)amine are disclosed, together with the use of such derivatives and of bis(1,3-dihydroxy-prop-2-yl)amine itself in the preparation of polymers, in particular dendrimers. Some of the derivatives may be useful as non-ionic surfactants.

Abstract: Polyalkeneamines of the formula (I) where R1, R2, R3, R4, R5 and R6 may have different meanings, are prepared by a process in which a polyalkene epoxide is reacted with an amine and the amino alcohol is dehydrated and reduced to give the compound of the formula (I).

Abstract: Inclusion of a branched alcohol in the catalytic hydrogenation reaction involving an aliphatic nitro compound dramatically increases the efficiency of the conversion of nitro groups into amino groups. This discovery is of particular value in the production of polyalkyleneamines via nitration of a polyalkene, such as a polybutene, and its subsequent reduction. The polyalkyleneamines so produced are useful as dispersant additives for motor oils and fuels.

Abstract: This invention relates to a method for the production of a sphingoid base according to formula comprising the steps of (1) dissolving a starting compound according to formula III or a salt thereof in a substantially inert solvent, (2) protecting the NH2 group with a NH2 protecting group, (3) activating the C-4 HR3 group for an elimination reaction with the C-5 HR4 group, (4) causing an elimination reaction to take place to form a double bond between the C-4 and C-5 carbon atom, and (5) removing the NH2 protecting group.

Abstract: The present invention provides amine derivatives represented by formula I, its isomers, racemes or optical isomers, pharmaceutical salts thereof, its amides or esters, pharmaceutical compositions containing said compounds and the preparation methods thereof. The invention also relates to the use of the above mentioned compounds in the preparation of drugs for the prophylaxis or treatment of cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasm as well as ischemic and anoxic nerve injury. The above compounds can be used to treat hypertension, angina diaphragmatic, myocardial infarction, congestive heart failure, arrhythmia, diabetes, spasmodic bronchial diseases, spasmodic bladder or ureter diseases, and depression.

Abstract: The present invention relates to a phytandiol amine derivative represented by the following formula (I) and compositions for treating acne comprising the same: (I) wherein each of Y and Z is OH with the proviso that X is NH2, each of X and Z is OH with the proviso that Y is NH2, and each of X and Y is OH with the proviso that Z is NH2.

Abstract: The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Abstract: Herein are disclosed a process for increasing in purity, or purifying, an N-protected-&bgr;-aminoalcohol which process comprises (i) adding water to a polar organic solvent in which an N-protected-&bgr;-aminoalcohol such as a (2R,3S)-or (2S,3R)-3-tert-butoxycarbonylamino-1-halo-2-hydroxy-4-phenylbutane or the like, or (ii) crystallizing such an N-protected-&bgr;-aminoalcohol from a diol or a diol-based mixed solvent, and a process for producing the corresponding N-protected-&bgr;-aminoepoxide which process comprises treating, with a base, the thus purity-enhanced N-protected-&bgr;-aminoalcohol. Such N-protected-&bgr;-aminoalcohols and N-protected-&bgr;-aminoepoxides are both useful as synthetic intermediates for medicine compounds, such as, e.g., HIV protease inhibitor and the like.

Abstract: Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to, porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.

Abstract: The present invention relates to novel tertiary alkanolamines useful as catalysts for preparing polyurethane foams and as additives to reduce the dynamic surface tension of aqueous solutions.

Abstract: The use of at least one substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compound and/or one of the enantiomers thereof and/or one of the diastereomers thereof and/or one of the physiologically acceptable salts thereof for producing a medicament that has an N-methyl-D-aspartate-(NMDA)-antagonistic effect.

Abstract: A process to prepare an improved fluid rare earth phosphate catalyst composition useful in preparing alkylene oxide adducts of organic compounds having active hydrogen atoms is provided. The catalyst is prepared by dissolving a rare earth salt in a C9-C30 active hydrogen containing organic compound and then adding phosphoric acid to the organic compound rare earth mixture.

Abstract: When the reaction solution formed during the addition of an alkylene oxide to an active hydrogen-containing compound has viscosity of not less than 10 mPa·s, this invention provides a method for stirring the reaction solution by the rotation of a vane or vanes continuously disposed in the vertical direction within an agitating reaction vessel in such a manner that the numerical value C represented by the following formula (1): C=A/(h2−h1)  (1) (wherein A denotes the length (m) of the vane or the vanes newly immersed by the supply of alkylene oxide, h1 denotes the height (m) of the liquid level before the supply of alkylene oxide, and h2 denotes the height (m) of the liquid level after the supply of alkylene oxide) may be not less than 0.5. By employing the method of this invention, it is made possible to effect addition of an alkylene oxide to the active hydrogen-containing compound with high efficiency.

Abstract: The present invention relates to a continuous process for the manufacture of triethanolamine (TEA) comprising, in succession: (i) a step of synthesizing the TEA by continuously bringing ammonia into contact with ethylene oxide under conditions allowing the formation of a reaction mixture comprising mono-, di- and triethanolamines, (ii) a step of continuously separating the ammonia that has not reacted from the reaction mixture and (iii) a step of continuously separating the TEA from the mixture resulting from step (ii). The process is characterized in that a specific mixture of alkanolamines, comprising TEA and from 0.5 to 50% by weight of at least one secondary dialkanolamine, is prepared or isolated from the mixture resulting from step (ii), and in that the TEA is separated and isolated with a degree of purity equal to or greater than 99.2% by weight, by a continuous distillation of the specific mixture of alkanolamines.

Abstract: This invention relates to an improvement in a process for effecting decolorization of an alkanolamine by subjecting the alkanolamine to hydrogenation in the presence of a hydrogenation catalyst.

Abstract: N-Substituted glucamine compounds of formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections the compounds of formular I may be used alone, or in combinatioin with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combination of such other agents.

Abstract: Alkali metal salt of formula (I): MOYXR1 (I), and its solution can be prepared in high yields, particularly high space-time yields, and with high purities by reacting an alcohol of the formula (Ia): HOYXR1 (Ia), in a solvent mixture with an alkali metal salt of formula (II): MOR2 (II), or by reacting the alcohol (Ia) in a solvent mixture with an alkali metal hydroxide. Part of the liberated alcohol of formula (IIa): HOR2 (IIa) or a part of the liberated water is distilled from the solvent mixture, initially, without addition of an entrainer. Subsequently, a remainder of the liberated alcohol of formula (IIa) or the liberated water is distilled from the solvent mixture with the aid of at least one organic solvent as entrainer. In formula (I) and in formula (II), M is Li, Na, K, Rb or Cs.

Abstract: Compounds, in particular those based on polyisobutyleneamines, are suitable as emulsifiers for water-in-oil emulsions and are used in particular as additives for fuels and lubricants.

Abstract: A process for producing an alkanolamine includes supplying a reactive distillation apparatus having an inner contacting surface which simultaneously facilitates a reaction process and a distillation process, feeding a first reactant including an amine represented by R′3-XNHX, wherein R′ is a hydrocarbon group, and X is 1, 2, or 3, feeding a second reactant including an akylene oxide represented by R″O, wherein R″ is a C2-C10-alkylene, feeding a catalyst in an amount from 0% to about 15% by weight of a mixture of the first reactant, the second reactant and the catalyst; recycling an overhead output from an overhead portion including an unreacted portion of the amine and the catalyst to achieve a substantially total reflux of the amine and the catalyst, and collecting a product output including an alkanolamine, the alkanolamine being a member selected from the group consisting of a monoalkanolamine, a dialkanolamine, and a trialkanolamine.

Abstract: Process for the perfluoropolyether preparation having reactive end groups —CH2NH2, —CHO, —CH2OH, by reduction of the corresponding perfluoropolyethers having —CN, —COCl, —CHO end groups by using gaseous hydrogen in the presence of a catalyst constituted by Pd, Rh, or Ru, supported on solid metal fluorides, at a temperature from 20° C to 150° C and under a pressure between 1 and 50 atm.

Abstract: Disclosed are multibinding compounds which are &bgr;2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, and bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Abstract: A process for preparing regioselectively an optically active 1-halogeno-2-hydroxypropyl compound of the following formula; 1